Axiom Bio

Name: Axiom Bio
Brand: Axiom Bio

AI Native

Eliminate molecular toxicity with AI models which outperform physical experiments

Est 2024|Valuation $121M|Raised $30M

LinkedIn 2K|Website|FTEs 24|HQ San Francisco, California, US

01Competitive Landscape

Narrative competitive analysis

- Axiom Bio vs DILIsym: - Axiom emphasizes higher-throughput data-driven prediction based on human hepatocyte datasets and statistical models. DILIsym focuses on mechanistic systems toxicology and simulation. Buyers seeking mechanistic hypothesis testing and formal QST workflows may prefer DILIsym; buyers seeking scalable screening with model-driven risk estimates may consider Axiom if validation and applicability domain meet their requirements. - Axiom Bio vs ADMET Predictor / Percepta / QikProp: - ADMET-focused tools provide broad endpoint coverage useful in many medchem workflows. Axiom’s focus is presented as concentrated on human-cell-derived liver risk prediction tied to exposure—this is a narrower, clinically-oriented endpoint set. - Axiom Bio vs organ/tissue automation players (e.g., Vivodyne): - Organ/tissue vendors emphasize wet-lab automation and experimental throughput; Axiom emphasizes data-driven prediction using human-cell experiments and modeling. Some buyers may combine experimental platforms with in silico prediction.

	Axiom Bio	Simulations Plus DILIsym	Schrödinger QikProp
Starting Price	Not public (enterprise/pilot-based); vendor-reported per-compound ranges exist but are vendor-provided	Not public; access models vary and are often consortium/membership-based	Not public (quote-based licensing typical)
Best For	Early DILI risk triage using primary human hepatocyte data combined with statistical/ML models	Mechanistic quantitative systems toxicology (QST) for liver injury hypothesis testing and simulation	Rapid ADME/physicochemical property estimations integrated into medchem workflows
Key Strength	Uses primary human liver cell experimental data and data-driven models to produce clinical-risk-focused outputs (vendor-provided evidence)	Mechanistic liver injury simulation framework used in industry contexts	Integration with a broader computational chemistry ecosystem; widely used for property estimation
Key Weakness	Limited publicly available independent customer evidence; benchmark methodology transparency is limited in public materials; security attestations not fully visible	Can be expertise-intensive; access and complexity can be a barrier	Not DILI-specific for clinical liver outcome prediction; may require complementary tools for hepatotoxicity risk

01Competitive Landscape

Narrative competitive analysis

Axiom Bio vs DILIsym:
- Axiom emphasizes higher-throughput data-driven prediction based on human hepatocyte datasets and statistical models. DILIsym focuses on mechanistic systems toxicology and simulation. Buyers seeking mechanistic hypothesis testing and formal QST workflows may prefer DILIsym; buyers seeking scalable screening with model-driven risk estimates may consider Axiom if validation and applicability domain meet their requirements.
Axiom Bio vs ADMET Predictor / Percepta / QikProp:
- ADMET-focused tools provide broad endpoint coverage useful in many medchem workflows. Axiom’s focus is presented as concentrated on human-cell-derived liver risk prediction tied to exposure—this is a narrower, clinically-oriented endpoint set.
Axiom Bio vs organ/tissue automation players (e.g., Vivodyne):
- Organ/tissue vendors emphasize wet-lab automation and experimental throughput; Axiom emphasizes data-driven prediction using human-cell experiments and modeling. Some buyers may combine experimental platforms with in silico prediction.

	Axiom Bio	Simulations Plus DILIsym	Schrödinger QikProp
Starting Price	Not public (enterprise/pilot-based); vendor-reported per-compound ranges exist but are vendor-provided	Not public; access models vary and are often consortium/membership-based	Not public (quote-based licensing typical)
Best For	Early DILI risk triage using primary human hepatocyte data combined with statistical/ML models	Mechanistic quantitative systems toxicology (QST) for liver injury hypothesis testing and simulation	Rapid ADME/physicochemical property estimations integrated into medchem workflows
Key Strength	Uses primary human liver cell experimental data and data-driven models to produce clinical-risk-focused outputs (vendor-provided evidence)	Mechanistic liver injury simulation framework used in industry contexts	Integration with a broader computational chemistry ecosystem; widely used for property estimation
Key Weakness	Limited publicly available independent customer evidence; benchmark methodology transparency is limited in public materials; security attestations not fully visible	Can be expertise-intensive; access and complexity can be a barrier	Not DILI-specific for clinical liver outcome prediction; may require complementary tools for hepatotoxicity risk

Axiom Bio

01Competitive Landscape

Narrative competitive analysis

02Market Map

01Competitive Landscape

Narrative competitive analysis

02Market Map